CRC
California Resources Corporation
stock NYSE

CRC as the base case plus pancreas as upside is a clean setup. If they reuse the ColoAlert workflow and keep costs down, that’s legit platform leverage.

Pancreatic cancer kills fast. Annual deaths are \~466,000 globally with a fatality rate near 93 percent. Early detection is rare, which is why a credible screen would be a big deal. MYNZ reported feasibility for PancAlert with 100 percent sensitivity and 95 percent specificity in early testing. It is early stage, but it uses the same mRNA plus analytics playbook the company applies in CRC.
CRC remains the core. ColoAlert is already used in Europe, now inside DoctorBox in Germany, and pooled next gen accuracy is quotable at \~92 percent CRC sensitivity, \~82 percent advanced adenomas, and \~95.8 percent high grade dysplasia. If the pancreas program advances with a blinded validation plan, a funded study timeline, and reuse of the ColoAlert workflow, the platform story gains real weight without heavy capex.
Do Your Own DD.

Coverage details will decide durability. In Germany, colonoscopy and FIT are generally covered for eligible adults. DNА stool tests can be self pay or covered inside pilots and specific plans. DоctorBox supports both flows. For readers trying to price МYNZ, ask for hard mix data and timing. Whаt percentage of CоloAlert orders are reimbursed versus self pay. Whаt is the average out of pocket where self pay applies. How many insurer or employer pilots are live, how many renew, and how many days from claim to cash.
Pair the economics with the medical need and accuracy. CRC is \~1.9М nеw cases and \~935,000 deaths each year worldwide. Germany contributes roughly 60,000 cases. Pooled next gen CоloAlert read is about 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high grade dysplasia. If reimbursement share rises while completion holds and turnaround stays tight, Europe becomes a durable revenue leg before U.S. milestones.
Neеdless to add, once insurance money is involved, it is a proper catalyst by itself.

If you want to judge МYNZ on execution, track the same four numbers every Friday for the next month. DoctоrBox gives at-home reach in Germany with 1,000,000 plus users and 10M plus results. Germany sees about 60,000 new colorectal cancer cases each year, while globally CRC is \~1.9M cases and \~935,000 deaths. Early detection matters. Pooled next gen CоloAlert performance is about 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high grade dysplasia.
Scoreboard to request from the company:
* App to order conversion percentage
* Completed kits per week
* Median turnaround time and failure or retest rate
* Percent of positives that reach colonoscopy within 30 days
If those trend up for four weeks, investors can model a European run rate while the U.S. feasibility timeline firms up. If not, it stays a headline. Which single metric would convince you first that adoption is real: conversion, completions, or colonoscopy follow through?
Not financial advice. Do your own research.

In shaky markets, recurring healthcare spend tends to hold. Preventive cancer screening is one of those lines. Colorectal cancer is roughly 1.9 million new cases and about 935,000 deaths per year worldwide. Five-year survival is near 90 percent when localized, but around 13 percent when distant. That math is why payers keep funding early detection even when risk assets wobble.
For MYNZ, the Europe-first story is tangible. ColoAlert is marketed via partner labs and now sits inside DoctorBox in Germany, an app with 1,000,000 plus registered users and 10M plus test results. Germany alone sees roughly 60,000 new CRC cases each year. Clinically, pooled next-gen performance is quotable: about 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high-grade dysplasia. The decentralized kit model lets new labs come online without heavy capex.
Eyeing this sector, names like this can re-rate fast.

Strategic buyers want distribution ready screening with real numbers. The clinical and market stats set the stage. CRC is about 1.9 million new cases and 935,000 deaths each year. Localized disease has roughly 90 percent five year survival vs about 13 percent when distant. Germany adds scale with around 60,000 cases per year.
To matter, a target needs accuracy and adoption. MYNZ’s pooled ColoAlert performance reads near 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high grade dysplasia. The funnel is improving through DoctorBox in Germany. On platform depth, the pancreatic program has reported feasibility with strong signal quality in early testing, which adds optionality if validated.
What would move a buyer to take a meeting: multicenter kit concordance, a visible European run rate with conversion and turnaround disclosed, failure and retest rates trending low, and a dated U.S. feasibility read with Quest lined up for scale. Hit two or three of those in the next quarters and the story shifts from speculative to strategic.
Do your own research

Strategic buyers don’t chase stories - they look for screening assets that are distribution-ready and backed by numbers. The clinical and market backdrop matters. Colorectal cancer sees \~1.9M new cases and \~935k deaths globally each year. Early-stage disease has \~90% five-year survival, versus \~13% once metastatic. Germany alone contributes \~60k cases annually, giving it real commercial weight.
For a target to be relevant, both performance and adoption have to show up. МYNZ’s pooled ColoAlert data shows \~92% CRC sensitivity, \~82% for advanced adenomas, and \~95.8% for high-grade dysplasia. On the commercial side, the German funnel is starting to improve via DoctorBox. Beyond CRC, the pancreatic program has reported feasibility with strong early signal quality - still early, but it adds optional upside if it holds.
What gets an acquirer to take a meeting? Things like: multicenter kit concordance, a visible European revenue run-rate with disclosed conversion and turnaround times, declining failure/retest rates, and a time-stamped U.S. feasibility update with Quest positioned for scale. Deliver two or three of those over the next few quarters, and the narrative shifts from speculative microcap to strategic asset.
Do your own research.

Colorectal cancer is huge and urgent. Roughly 1.9 million new cases and about 935,000 deaths worldwide each year. In the U.S., five year survival is near 90 percent when localized and about 13 percent when distant. Germany alone sees around 60,000 new cases per year. Early detection moves patients from late therapy to quick intervention.
For MYNZ, a single clean update can shift the multiple if it includes hard adoption data plus accuracy. ColoAlert’s pooled next gen read is roughly 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high grade dysplasia. Pair that with DoctorBox conversion, completed kits per week, median turnaround, and early reorders in Germany. Add a dated U.S. feasibility read and the path to a pivotal moves from talk to timeline.
If those metrics land together, investors can model real volume instead of headlines. If they do not, it remains a trading vehicle.
Do your own DD too

Big buyers just told the market where growth sits: cancer screening and precision diagnostics. Abbott agreeing to acquire Exact Sciences is not about one brand. It is a statement that early detection is strategic, scalable, and worth paying up for. If that is true for the giants, it sets a supportive backdrop for smaller platforms that already have product in use.
That is why I keep MYNZ on screen. ColoAlert is live in Europe through partner labs, with German distribution now boosted by DoctorBox. Clinically, pooled next gen reads are strong: roughly 92% CRC sensitivity, 82% advanced adenomas, 95.8% high grade dysplasia. The business model is kits plus partner labs, so volume can scale without heavy capex. What I want next: DoctorBox conversion and completions, early reorders by region, and a firm U.S. feasibility date that moves the FDA path from talk to timeline.

CRC as the base case plus pancreas as upside is a clean setup. If they reuse the ColoAlert workflow and keep costs down, that’s legit platform leverage.

Pancreatic cancer kills fast. Annual deaths are \~466,000 globally with a fatality rate near 93 percent. Early detection is rare, which is why a credible screen would be a big deal. MYNZ reported feasibility for PancAlert with 100 percent sensitivity and 95 percent specificity in early testing. It is early stage, but it uses the same mRNA plus analytics playbook the company applies in CRC.
CRC remains the core. ColoAlert is already used in Europe, now inside DoctorBox in Germany, and pooled next gen accuracy is quotable at \~92 percent CRC sensitivity, \~82 percent advanced adenomas, and \~95.8 percent high grade dysplasia. If the pancreas program advances with a blinded validation plan, a funded study timeline, and reuse of the ColoAlert workflow, the platform story gains real weight without heavy capex.
Do Your Own DD.

Coverage details will decide durability. In Germany, colonoscopy and FIT are generally covered for eligible adults. DNА stool tests can be self pay or covered inside pilots and specific plans. DоctorBox supports both flows. For readers trying to price МYNZ, ask for hard mix data and timing. Whаt percentage of CоloAlert orders are reimbursed versus self pay. Whаt is the average out of pocket where self pay applies. How many insurer or employer pilots are live, how many renew, and how many days from claim to cash.
Pair the economics with the medical need and accuracy. CRC is \~1.9М nеw cases and \~935,000 deaths each year worldwide. Germany contributes roughly 60,000 cases. Pooled next gen CоloAlert read is about 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high grade dysplasia. If reimbursement share rises while completion holds and turnaround stays tight, Europe becomes a durable revenue leg before U.S. milestones.
Neеdless to add, once insurance money is involved, it is a proper catalyst by itself.

If you want to judge МYNZ on execution, track the same four numbers every Friday for the next month. DoctоrBox gives at-home reach in Germany with 1,000,000 plus users and 10M plus results. Germany sees about 60,000 new colorectal cancer cases each year, while globally CRC is \~1.9M cases and \~935,000 deaths. Early detection matters. Pooled next gen CоloAlert performance is about 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high grade dysplasia.
Scoreboard to request from the company:
* App to order conversion percentage
* Completed kits per week
* Median turnaround time and failure or retest rate
* Percent of positives that reach colonoscopy within 30 days
If those trend up for four weeks, investors can model a European run rate while the U.S. feasibility timeline firms up. If not, it stays a headline. Which single metric would convince you first that adoption is real: conversion, completions, or colonoscopy follow through?
Not financial advice. Do your own research.

In shaky markets, recurring healthcare spend tends to hold. Preventive cancer screening is one of those lines. Colorectal cancer is roughly 1.9 million new cases and about 935,000 deaths per year worldwide. Five-year survival is near 90 percent when localized, but around 13 percent when distant. That math is why payers keep funding early detection even when risk assets wobble.
For MYNZ, the Europe-first story is tangible. ColoAlert is marketed via partner labs and now sits inside DoctorBox in Germany, an app with 1,000,000 plus registered users and 10M plus test results. Germany alone sees roughly 60,000 new CRC cases each year. Clinically, pooled next-gen performance is quotable: about 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high-grade dysplasia. The decentralized kit model lets new labs come online without heavy capex.
Eyeing this sector, names like this can re-rate fast.

Strategic buyers want distribution ready screening with real numbers. The clinical and market stats set the stage. CRC is about 1.9 million new cases and 935,000 deaths each year. Localized disease has roughly 90 percent five year survival vs about 13 percent when distant. Germany adds scale with around 60,000 cases per year.
To matter, a target needs accuracy and adoption. MYNZ’s pooled ColoAlert performance reads near 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high grade dysplasia. The funnel is improving through DoctorBox in Germany. On platform depth, the pancreatic program has reported feasibility with strong signal quality in early testing, which adds optionality if validated.
What would move a buyer to take a meeting: multicenter kit concordance, a visible European run rate with conversion and turnaround disclosed, failure and retest rates trending low, and a dated U.S. feasibility read with Quest lined up for scale. Hit two or three of those in the next quarters and the story shifts from speculative to strategic.
Do your own research

Strategic buyers don’t chase stories - they look for screening assets that are distribution-ready and backed by numbers. The clinical and market backdrop matters. Colorectal cancer sees \~1.9M new cases and \~935k deaths globally each year. Early-stage disease has \~90% five-year survival, versus \~13% once metastatic. Germany alone contributes \~60k cases annually, giving it real commercial weight.
For a target to be relevant, both performance and adoption have to show up. МYNZ’s pooled ColoAlert data shows \~92% CRC sensitivity, \~82% for advanced adenomas, and \~95.8% for high-grade dysplasia. On the commercial side, the German funnel is starting to improve via DoctorBox. Beyond CRC, the pancreatic program has reported feasibility with strong early signal quality - still early, but it adds optional upside if it holds.
What gets an acquirer to take a meeting? Things like: multicenter kit concordance, a visible European revenue run-rate with disclosed conversion and turnaround times, declining failure/retest rates, and a time-stamped U.S. feasibility update with Quest positioned for scale. Deliver two or three of those over the next few quarters, and the narrative shifts from speculative microcap to strategic asset.
Do your own research.

Colorectal cancer is huge and urgent. Roughly 1.9 million new cases and about 935,000 deaths worldwide each year. In the U.S., five year survival is near 90 percent when localized and about 13 percent when distant. Germany alone sees around 60,000 new cases per year. Early detection moves patients from late therapy to quick intervention.
For MYNZ, a single clean update can shift the multiple if it includes hard adoption data plus accuracy. ColoAlert’s pooled next gen read is roughly 92 percent CRC sensitivity, 82 percent advanced adenomas, and 95.8 percent high grade dysplasia. Pair that with DoctorBox conversion, completed kits per week, median turnaround, and early reorders in Germany. Add a dated U.S. feasibility read and the path to a pivotal moves from talk to timeline.
If those metrics land together, investors can model real volume instead of headlines. If they do not, it remains a trading vehicle.
Do your own DD too

Big buyers just told the market where growth sits: cancer screening and precision diagnostics. Abbott agreeing to acquire Exact Sciences is not about one brand. It is a statement that early detection is strategic, scalable, and worth paying up for. If that is true for the giants, it sets a supportive backdrop for smaller platforms that already have product in use.
That is why I keep MYNZ on screen. ColoAlert is live in Europe through partner labs, with German distribution now boosted by DoctorBox. Clinically, pooled next gen reads are strong: roughly 92% CRC sensitivity, 82% advanced adenomas, 95.8% high grade dysplasia. The business model is kits plus partner labs, so volume can scale without heavy capex. What I want next: DoctorBox conversion and completions, early reorders by region, and a firm U.S. feasibility date that moves the FDA path from talk to timeline.